Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCP 154526
说明： Selective, non-peptide CRF1 antagonist
化学名： N-Butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride
纯度： ≥99% (HPLC)
生物活性 for CP 154526
CP 154526 is a selective, non-peptide CRF1 receptor antagonist (Ki values are 2.7 and > 10000 nM for CRF1 and CRF2 receptors respectively). Blocks CRF-induced adenylate cyclase activation (Ki = 3.7 nM) and attenuates activation of the HPA axis by CRF. Displays anxiolytic-like activity in the rat elevated plus-maze test; brain penetrant.
许可信息
Sold for research purposes under agreement from Pfizer Inc.
化合物库 for CP 154526
CP 154526 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for CP 154526
| 分子量 | 400.99 |
| 公式 | C23H32N4.HCl |
| 储存 | Desiccate at +4°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 257639-98-8 |
| PubChem ID | 11475094 |
| InChI Key | ZWDLBNCJWNENFF-UHFFFAOYSA-N |
| Smiles | CC1=CN(C3=C(C)C=C(C)C=C3C)C2=C1C(N(CC)CCCC)=NC(C)=N2.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for CP 154526
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 20.05 | 50 | |
| ethanol | 20.05 | 50 |
制备储备液 for CP 154526
以下数据基于产品分子量 400.99。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 4.99 mL | 24.94 mL | 49.88 mL |
| 2.5 mM | 1 mL | 4.99 mL | 9.98 mL |
| 5 mM | 0.5 mL | 2.49 mL | 4.99 mL |
| 25 mM | 0.1 mL | 0.5 mL | 1 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for CP 154526
参考文献 for CP 154526
参考文献是支持产品生物活性的出版物。
Lundkist et al (1996) A non peptidic cortico. releasing factor receptor antagonist attenuates fever and exhibits anxiolytic activity. Eur.J.Pharmacol. 309 195 PMID: 8874139
Hodgson et al (2007) Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol.Biochem.Behav. 86 431 PMID: 17291571
Schulz et al (1996) CP-154,526: a potent and selective nonpeptide antagonist of cortico. releasing factor receptors. Proc.Natl.Acad.Sci.USA 93 10477 PMID: 8816826
If you know of a relevant reference for CP 154526, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: CP 154526, CP 154526 supplier, Selective, non-peptide, CRF1, antagonists, Corticotropin-Releasing, Factor1, Receptors, CP154526, Pfizer, 2779, Tocris Bioscience
1 篇 CP 154526 的引用文献
引用文献是使用了 Tocris 产品的出版物。 CP 154526 的部分引用包括：
Klampfl et al (2016) CRF-R1 activation in the anterior-dorsal BNST induces maternal neglect in lactating rats via an HPA axis-independent central mechanism. Biochem Biophys Res Commun 64 89 PMID: 26630389
您是否知道使用了 Tocris CP 154526 的优秀论文？ 请告知我们.
CP 154526 的评论
目前没有该产品的评论。 Be the first to review CP 154526 and earn rewards!
Have you used CP 154526?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.